It's not about eating humble pie, being right or wrong, or about making or losing money to me. I've been on both sides of all fences. I won't base whether I've been right or wrong on top line results unless they were to be clearly bad. The current OLE patient dosing trial will also play a part in my decisions. Similar with FragileX or MS. I'm not the only person who thinks the drug shows promise which is why the drug is being researched independently over the entire World. I imagine that will continue regardless of this year's AD trial results. I would be disappointed but not necessarily for the reasons some might think.
Market Data 
Markets 
AI
